Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Oncology Initiates $2.2M Direct Stock Offering

NEW YORK – Predictive Oncology said Thursday that it has agreed to a direct offering of 1,396,826 shares at $1.575 per share, for gross proceeds of about $2.2 million.  

The company also will issue new investors an equal number of unregistered warrants at $1.45 per share. These warrants will expire 5.5 years from issuance.  

H.C. Wainwright is the exclusive placement agent for this offering, which is priced at-market, per Nasdaq rules 

The Eagan, Minnesota-based developer of artificial intelligence and other bioinformatics technologies for precision medicine and drug discovery said that it would apply as much as $487,000 of the net proceeds to repay debts to Oasis Capital. The rest would be used as working capital. 

Formerly known as Precision Therapeutics, Predictive Oncology had another offering of $3.2 million in October when the stock was worth just $0.50 per share. 

The firm operates through three subsidiaries: Helomics, which provides tumor-analysis services for treatment personalization and new drug development; TumorGenesis, which is developing patient-derived tumor models for precision drug testing; and Skyline Medical, which markets a US Food and Drug Administration-approved system for automated medical fluid disposal. 

In mid-afternoon trading Thursday on the Nasdaq, Predictive Oncology stock was down 12 percent to $1.32. 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.